Background: Vascular smooth muscle cell (VSMC) proliferation following arterial injury plays a critical role in a variety of vascular proliferative disorders, including atherosclerosis and restenosis after balloon angioplasty. In this study, we tested the hypothesis that localized arterial infection at the time of balloon angioplasty with an adenovirus (ADV-tk) encoding the herpes simplex virus thymidine kinase gene (HSVtk), followed by systemic ganciclovir administration, can inhibit VSMC proliferation and neointima formation in a well-characterized model of arterial injury
and restenosis. Materials and Methods: The left carotid arteries of 31 male Sprague-Dawley rats were subjected to balloon angioplasty and immediately infected with 2 x 109 pfu of either ADV-tk or a control adenovirus that does not encode a recombinant protein (ADV-AE1).
Twenty-four hours after injury, animals from each experimental group were randomized to receive a course of systemic ganciclovir (ADV-tk/+GC, ADV-AE1/+GC) or saline (ADV-tk/-GC, ADV-AE1/-GC). VSMC DNA synthesis was measured by 5'-bromodeoxyuridine (BrdU) incorporation 2-4 days after balloon injury. The extent of restenosis, expressed as the neointima to media (I/M) area ratio was determined by digital planimetry 20 days after balloon injury in each of the four treatment groups. Immunohistochemistry using a mAb to von Willebrand factor (vWF) was used to determine the effects of ADV-tk infection and ganciclovir treatment on re-endothelialization of the carotid arteries 20 days following balloon angioplasty.
Results: Forty-one percent of the medial VSMCs in the ADV-tk/-GC arteries were labeled with BrdU 4 days after balloon injury. In contrast, ADV-tk infected animals that were treated with systemic ganciclovir (ADV-tk/+GC) displayed a 40% reduction in BrdUstaining medial VSMCs (p < 0.03). I/M area ratios of the three control groups were 1.17 ± 0.18 (ADV-tk/ -GC, n = 5), 1.15 ± 0.10 (ADV-AEl/+GC, n = 6), and 0.91 ± 0.08 (ADV-AEI/-GC, n = 6). These differences were not statistically significant (p > 0.05). In contrast, the ADV-tk/+GC animals (n = 6) displayed an I/M area ratio of 0.49 ± 0.13 which was significantly lower than that seen in each of the three control groups (p < 0.02). None of the treated animals showed evidence of significant organ toxicity at autopsy. A regenerated endothelium was observed in the ADVtk/+GC animals 20 days after balloon injury. Conclusions: Localized arterial infection with ADV-tk at the time of balloon angioplasty followed by systemic ganciclovir therapy reduces VSMC proliferation and neointimal expansion in the rat carotid artery injury model. Moreover, combined treatment with ADV-tk and systemic ganciclovir does not result in systemic toxicity and appears to selectively eliminate proliferating VSMCs, while preserving the capacity of the injured arterial segments to re-endothelialize within 3 weeks of injury. Taken together, these results support the feasibility of using this gene therapy approach for the treatment of human vascular proliferative disorders.
INTRODUCTION
Vascular smooth muscle cells (VSMCs) play an important role in both the normal and pathological responses of the arterial wall to injury (1).
Nonproliferating (Go) VSMCs are normally localized to the arterial tunica media where they regulate vascular tone and local perfusion in response to a variety of neurohumoral signals. Arterial injury results in the migration of VSMCs from the tunica media into the intima where they proliferate and elaborate extracellular matrix (1, 2, 3) . This proliferation contributes to the pathogenesis of a number of cardiovascular disorders, including atherosclerosis and restenosis which occurs in 30-50% of patients following percutaneous transluminal coronary angioplasty (PTCA) (2-5). Molecular approaches designed to limit VSMC proliferation specifically at sites of arterial injury could both lead to a better understanding of the pathogenesis of vascular proliferative disorders and aid in the rational design of novel gene-based therapies for these disorders in humans.
Herpes Simplex virus thymidine kinase (HSV-tk) phosphorylates the nucleoside analog ganciclovir, converting it into an active form that inhibits DNA synthesis and kills proliferating cells (6, 7) . Recent studies have demonstrated that forced expression of the HSV-tk gene, when combined with ganciclovir treatment can be used as an effective cytotoxic therapy for tumor cells both in vitro and in vivo (8) (9) (10) (11) (12) (13) . Interestingly, in these studies, expression of the HSV-tk gene in only a small proportion of the tumor cells resulted in widespread cell death due to a "bystander effect." We and others have recently demonstrated that replication-defective adenoviruses can be used to efficiently transfer recombinant genes into VSMCs in localized segments of the arterial wall in vivo (14) (15) (16) (17) . In the studies described in this report, we have tested the hypothesis that localized infection of the arterial wall at the time of balloon angioplasty with a replication-defective adenovirus encoding the HSV-tk gene when combined with systemic ganciclovir treatment can be used to inhibit VSMC proliferation and neointima formation in the rat carotid artery model of vascular injury and restenosis.
MATERIALS AND METHODS
Recombinant Adenoviruses. ADV-tk is an E1-and E3-deleted, replicationdefective, Ad 5-derived adenovirus which contains the HSV-tk gene under the transcriptional control of a polyoma enhancer/promoter (15) .
The ADV-AE 1 control virus is identical to ADV-tk but lacks the HSV-tk gene and the polyoma enhancer/promoter (15) . Both viruses were prepared and grown as high titer stocks in 293 cells as described previously (14) . All virus stocks were purified by centrifugation in discontinuous CsCl gradients and dialyzed against phosphatebuffered saline (PBS) (14) . Viruses were diluted for storage in 13% glycerol-PBS solution to yield a final titer of 7.5 X 109 pfu/ml.
In Vivo Gene Transfer and Drug Therapy Localized arterial infection with the recombinant adenoviruses following balloon injury was performed as described previously (14) . Briefly, the left common carotid arteries of adult male Sprague-Dawley rats were injured by dilatation using a 2 French Fogarty catheter (18) . Following injury, the instrumented carotid artery segments were isolated using microvascular clamps. BrdU incorporation in vivo as described previously (14) . Two days after balloon injury and virus infection, animals received four subcutaneous injections of BrdU (25 mg/kg every 12 hr). Animals were sacrificed 4 days after balloon injury and the carotid arteries were fixed in situ by intravascular administration of 4% paraformaldehyde (4, 19, 20) . The carotid arteries were dissected free of connective tissue and paraffin-embedded. Deparaffinized 5-,um sections were treated with 3% H202 in methanol and permeablized by incubation in 0.4% pepsin and 3.3 M HCI. Sections were blocked by incubation for 20 minutes at room temperature in 1.5% horse serum and incubated overnight at 4°C with a 1:100 dilution of an a-BrdU mAb (Becton-Dickinson, San Jose, CA). The sections were then incubated for 30 min at room temperature with a 1:200 dilution of biotinylated horse a-mouse Ig antiserum, followed by a 30-min incubation at room temperature with avidin-conjugated horseradish peroxidase (Vectastain Elite ABC kit; Vector laboratories, Burlingame, CA). Sections were then treated with diaminobenzidine (DAB) and counterstained with hematoxylin and eosin. Total nuclei and BrdU-positive nuclei were counted manually. At least 500 cells from two sections taken at least 1 mm apart were assessed in duplicate for each animal. To ensure that all animals received adequate doses of BrdU, sections of terminal ileum were used as positive controls. All slides were coded and determinations were performed by an observer blinded to the experimental conditions. Statistical analyses were performed using Sigmaplot (Jandel Scientific, Corte Madera, CA).
Histological Analyses
Carotid arteries were harvested as described previously (14) 20 days after balloon injury and virus infection. Arteries were paraffin-embedded and 5-,tM sections were stained with hematoxylin and eosin. Neointimal and medial boundaries were determined on coded slides in two independent laboratories (JML and EGN) by investigators who were blinded to the experimental conditions. Areas were determined using digital planimetry of tissue sections using MOCHA software (Jandel Scientific, Corte Madera, CA) and the Image-I System (Universal Imaging, Westchester, PA) as described previously (14, 21) . The neointimal and medial (I/M) crosssectional areas were measured from four sections of each artery. Each section was obtained from the 1-cm segment of common carotid artery that was subjected to both balloon injury and ADV infection. The mean of these four determinations was used to calculate the I/M cross-sectional ratio for each animal. Tissue samples were also obtained from the brain, heart, lung, liver, spleen, aorta, skeletal muscle, kidney, intestine, and testes from each animal, and hematoxylin and eosin stained sections from each tissue were examined for pathology by an experimental pathologist (DG) blinded to the experimental conditions.
Immunohistochemistry
Carotid arteries harvested 20 days after balloon injury were fixed and embedded as described above. Immunostaining for vWF was performed as described previously (14) . Briefly, 5-Am sections were stained with a commercially available a-vWF mAb (Dako, Santa Barbara, CA) followed by a biotinylated goat anti-mouse IgG using an automatic immunostainer (Ventana Immunosystems, Tucson, AZ). Slides were developed with avidin-conjugated alkaline phosphatase and fast red-naphthol (Ventana Immunosystems) according to the manufacturer's instructions. In negative control experiments, the same sections were stained with an isotype matched control mAb. Sections of human tonsil were used as positive controls.
Statistical Analysis
All values are expressed as mean ± SEM. Statistical analyses were performed using Sigmaplot software (Jandel Scientific, Corte Madere, CA) on an Apple Macintosh Quadra computer. The Student's t test was used to evaluate differences between the experimental groups.
RESULTS

Inhibition of VSMC Proliferation by ADV-tk Infection Followed by Systemic
Ganciclovir Therapy Balloon injury of the rat carotid artery is a well characterized animal model of arterial restenosis that has been shown to be highly dependent upon VSMC proliferation and migration (14, 16, (18) (19) (20) . Previous studies in this model have shown that medial VSMCs begin to proliferate within 2 days after balloon injury (14, 18) . Medial VSMC proliferation reaches a peak within 4 days after injury, with approximately 40% of the cells proliferating as measured by incorporation of BrdU (14) . Between 4 and 6 days after injury, significant numbers of proliferating VSMCs can be detected in the neointima of the injured vessel. By 20 days after injury, all of the arteries demonstrate significant neointima formation and VSMC proliferation is no longer detectable in either the media or the neointima of the injured vessel (14, 18, 19) .
To determine the effects of localized ADV-tk infection plus systemic ganciclovir treatment on VSMC groups displayed I/M area ratios of 1.17 ± 0.18 (ADV-tk/-GC), 1.15 ± 0.10 (ADV-AE1/+GC), and 0.91 ± 0.08 (ADV-AEI/-GC) (Fig. 3) . These I/M ratios were not statistically different from each other (P > 0.05). In contrast, the combination of ADV-tk infection and systemic ganciclovir therapy resulted in an I/M ratio of 0.49 ± 0.13, which represented a 58% reduction as compared with that in the ADV-tk/-GC control group, a 57% reduction as compared with the I/M ratio of the ADV-AEI/+GC control animals, and a 46% reduction as compared with the I/M ratio in the ADV-AE1/-GC treated controls (p < 0.02). Thus, localized ADV-tk infection at the time of arterial injury, followed by systemic administration of ganciclovir resulted in significant reductions in both VSMC proliferation and neointimal formation in the rat carotid artery model of restenosis.
Reendothelialization Following ADV-tk Infection and Systemic Ganciclovir Therapy Reendothelialization has been shown to play an important role in preventing thrombosis and inhibiting VSMC proliferation during the normal vascular response to injury (22) (23) (24) (25) (26) (17, 27 ). Thus, it was possible that ADV-tk infection followed by systemic ganciclovir therapy would inhibit the normal reendothelialization of the rat carotid artery following balloon angioplasty. To address this possibility, we used immunohistochemistry with an endothelial cell-specific a-vWF mAb to assess the extent of reendothelialization 20 days following ADV-tk infection and systemic ganciclovir therapy. As shown in Fig. 4A , the luminal surface of these arterial segments was lined with a monolayer of endothelial cells that stain with the a-vWF mAb. Thus, ADV-tk infection and ganciclovir therapy inhibits VSMC proliferation and neointimal formation while allowing efficient reendothelialization of the injured arterial segment within 20 days.
Lack of Significant Tissue Toxicity in the ADV-tk-Infected Animals Receiving Systemic Ganciclovir Therapy Because replication-defective adenovirus vectors have been shown to efficiently infect a wide variety of cell types in vitro and in vivo (17, (27) (28) (29) (30) (31) (32) , it was possible that intravascular infection with ADV-tk followed by systemic ganciclovir therapy would result in significant cytotoxicity in a variety of organs in vivo. To address this issue, tissue samples from brain, heart, lung, aorta, liver, kidney, spleen, intestine, testes, and skeletal muscle were examined by light microscopy. No significant pathologic lesions were observed in these tissues from animals in the four experimental groups. Of note, the infected carotid arteries showed occasional mononuclear cell infiltrates in the adventitia but no medial or neointimal inflammation, necrosis, or aneurysm formation.
DISCUSSION
Percutaneous transluminal coronary angioplasty (PTCA) remains a mainstay of therapy for symptomatic coronary artery disease (4, 5) . While this procedure is initially successful in relieving critical arterial stenoses in greater than 95% of pa- tients (1, 5) , a reactive VSMC proliferation ensues within the first 6 months after the procedure, leading to clinically significant intimal hyperplasia and restenosis in 30-50% of the treated arteries (2-5). Intimal hyperplasia following PTCA is likely an exaggerated form of the response to arterial injury common to a wide variety of vascular proliferative disorders including atherosclerosis (1) (2) (3) . Numerous pharmacologic approaches, including antiplatelet agents, anticoagulants, angiotensin-converting enzyme antagonists, and cytotoxic drugs, have failed to inhibit restenosis in humans (33) (34) (35) (36) (37) . More recently, genetic approaches have been used both to better understand the molecular mechanisms underlying the VSMC proliferative response to arterial injury, and to form the basis for novel gene-based therapies for restenosis and other vascular proliferative diseases (14, 15, 20, 38) . One study has demonstrated that antisense oligonucleotides directed against the c-myb protooncogene could significantly inhibit restenosis when applied to the adventitial surface of the vessel (38) . More recently, the intraluminal administration of antisense oligonucleotides directed against PCNA and cdc2 complexed with hemagglutinating virus of Japan coated liposomes was shown to inhibit restenosis in the rat carotid artery model of injury (20) . Although encouraging, these antisense approaches may be limited by significant batch to batch variability in the antisense oligonucleotides themselves, and by the lack of a reliable intravascular delivery system.
Replication-defective adenoviruses represent an attractive vector system for programming transient recombinant gene expression in localized segments of the arterial wall. These vectors have been show to efficiently infect VSMCs both in vitro and in vivo (14) (15) (16) (17) . They can be prepared as high titer stocks and delivered to the intraluminal surface of the vessel using a variety of catheters (14) (15) (16) (17) . As compared with most other viral vectors, they have a favorable safety profile (17, 31, (39) (40) (41) . Thus, adenoviruses do not integrate into the host genome and have not been associated with human malignancies (28, (39) (40) (41) (42) . Furthermore, adenoviruses cause only mild upper respiratory infections in humans (43) , and adenovirus vectors have been used safely to vaccinate large numbers of military recruits (42) . Most importantly, previous studies have shown that El-deleted replication-defective adenovirus vectors program recombinant gene expression for only [14] [15] [16] [17] [18] [19] [20] [21] days after in vivo administration (17, 28, 32, 44, 45 (33, 34) .
It is important to consider the mechanism by which ADV-tk/+GC therapy inhibits neointimal formation and restenosis following arterial injury. The protocol for adenovirus-mediated intravascular gene transfer used in our studies results in efficient in vivo gene transfer into medial VSMCs in the injured arterial segment (14, 15) . Thus, it is possible that the observed inhibition of restenosis reflects a direct cytotoxic effect of ganciclovir on the adenovirus-infected VSMCs. Alternatively, the inhibitory effects of this approach may reflect the previously described, but poorly understood "bystander effect" associated with HSV-tk expression + ganciclovir treatment (8, 9) . This effect was first described in tumor cells transduced with the HSV-tk gene and treated with ganciclovir (9) . In these initial experiments ganciclovir was shown to be cytotoxic to both transduced and nontransduced tumor cells in the same culture dish. Subsequent studies showed that expression of HSV-tk in only 25% of cultured primary porcine VSMCs was sufficient to kill approximately 75 % of the cells in the culture dish (1 5) . Although this bystander effect has been clearly demonstrated in vitro, it is currently difficult to assess the role of this cytotoxic mechanism in vivo.
It is noteworthy that the experimental protocol described in this report utilized a 5-min infection with adenovirus as compared with the 20 min incubation used in the porcine model (15) . Thus, it may be possible to significantly reduce the times of infection following balloon angioplasty, an important consideration for limiting myocardial ischemia in humans following PTCA. Finally, as opposed to previous protocols (16) The efficacy and safety of ADV-tk followed by ganciclovir therapy in two animal models of restenosis suggests the possible utility of this approach for the therapy of human restenosis following PTCA. However, it will be important to demonstrate the efficacy of this treatment in atherosclerotic models of balloon angioplasty prior to the initiation of human clinical trials.
